trending Market Intelligence /marketintelligence/en/news-insights/trending/y0gbihtsvcaqljadvsro9q2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Acorda Therapeutics seeks European approval for Parkinson's treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Acorda Therapeutics seeks European approval for Parkinson's treatment

Acorda Therapeutics Inc. is seeking European Medicines Agency approval to sell its Parkinson's drug Inbrija to patients who are taking carbidopa/levodopa, one of the main drug combinations to treat the disease.

The company filed a marketing authorization application with the regulator, seeking approval for the drug, which is meant to treat patients experiencing so-called off periods — times when the effects of a medication start to wear off in between doses, resulting in the re-emergence of Parkinson's symptoms.

Acorda's submission is supported by the results of a phase 3 trial in which Inbrija significantly improved the motor functions of the patients compared to placebo.

The drug is also under review by the U.S. Food and Drug Administration, which is expected to make a decision Oct. 5.